Icade: Invest Securities cuts target price
(CercleFinance.com) - Invest Securities maintains its buy rating on Icade shares, reducing its target price for them from 57.
2 euros to 55.1 euros.
The broker says that the sale of all the group's healthcare assets will be carried out in three phases - spread through to 2025.
Given the strong demand for healthcare assets and the benchmark set by phase 1, analysts model a -5% discount on asset valuations for phases 2 and 3. The lead buyer, Primonial, is not legally obliged to acquire the assets in phases 2 and 3, which could potentially complicate transactions, it says.
However, Invest remains confident that the three phases will be completed successfully and will generate an excessive amount of cash (E3bn), with many potential uses.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.